Enhancing the Efficiency and Sustainability of Oligonucleotide Manufacturing

Oligonucleotide therapeutics are moving from rare-disease to large-indication manufacturing at a pace that is outstripping the infrastructure, methods, and commercial frameworks the sector has built to date. Programs targeting hundreds of kilograms per year are now within planning horizons, forcing decisions that must be made now, under uncertainty and without established playbooks. To confront this, 36 senior experts from industry and academia met across two days of pre-competitive discussion. This report sets out where the field stands, what the most experienced people in the sector believe needs to change, and where coordinated action across organizations is both necessary and achievable, giving readers a clear picture of the critical decisions, the available options, and the cost of deferring them.

Read the full report below

Please enter your email to access content Read now